RankAlpha logo
Back to Rankings

STTK

Shattuck LabsB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The bull case is still a monitoring-style biotech setup: March company disclosures pointed to a near-complete Phase 1 program, Q2 2026 human data, a possible Q3 2026 Phase 2 Crohn's start, and runway guidance into 2029 that included first-quarter ATM proceeds and warrant assumptions [#8-K-2026-03-05]. If the Phase 1 package shows clean safety, durable receptor occupancy, and a credible path into Crohn's disease, the stock could move above the current median target baseline, but the weak direct peer set limits confidence in any valuation read-through.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +1.5.
What can break
No new Q1 2026 company earnings filing was located in SEC sources checked on May 4, 2026, leaving surprise, guidance, and immediate post-print reaction evidence unavailable for this T+1 run.
Momentum
98
Value
41
Sentiment
39
Setup hits (3d)
— · Net —
AI TargetsBase $7.25 · Bull $9.50 · Bear $4.50
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net —
Target $15.80
Why
Momentum98 · Δ7d +1.5
Value41 · Δ7d -0.1
Sentiment39 · Δ7d -15.6
So what
Strength-led posture. Favor watchlist adds and disciplined entries.
Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits
Lead driver: Momentum · See technicals
Momentum
98
26% active weight
Current posture
7d trendFlat
Δ7d
+1.5
Δ21d
+86.4
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
39
34% active weight
Current posture
7d trendSoftening
Δ7d
-15.6
Δ21d
-17.0
Why this grade

Composite grade B. Momentum 97.9 / Value 41.1 / Sentiment 39.0

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$680.5M
Beta
1.53
Shares Out
90.37M
P/E (TTM) · Derived
-10.7
P/S (TTM)
246.16
P/FCF (TTM) · Derived
-8.67
Rev YoY
-66.6%
EPS YoY
-51.0%
Gross Margin
-264.3%
Op Margin
-5777.8%
Net Debt
-$75.64M
Current Ratio
22.06
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology